Room for improvement: diagnosing and managing acute coronary syndromes in persons with reduced eGFR

Area of Science:

• Nephrology
• Cardiology
• Clinical Medicine

Background:

• Cardiovascular events are the primary cause of mortality in patients with chronic kidney disease (CKD).
• Acute coronary syndrome (ACS) diagnosis and management present unique challenges in individuals with impaired kidney function.
• Reduced estimated glomerular filtration rate (eGFR) impacts cardiovascular risk and treatment strategies.

Purpose of the Study:

• To analyze the findings of the High-Sensitivity Troponin in the Evaluation of Patients With Suspected Acute Coronary Syndrome (HS-TATEP) trial specifically in patients with reduced eGFR.
• To discuss the complexities of diagnosing ACS in patients with CKD.
• To explore the differential management approaches for ACS in patients with normal versus reduced kidney function.

Main Methods:

• Retrospective analysis of data from the HS-TATEP trial.
• Focus on patient subgroups with varying levels of estimated glomerular filtration rate (eGFR).
• Comparative review of diagnostic and therapeutic strategies for ACS.

Main Results:

• Cardiovascular events are the leading cause of death in CKD patients.
• Analysis focused on HS-TATEP trial results within the reduced eGFR population.
• Observed differential management of ACS between patients with normal and reduced kidney function.

Conclusions:

• CKD significantly increases cardiovascular risk, with ACS being a major concern.
• Diagnostic and management strategies for ACS require careful consideration of kidney function.
• Further research is needed to optimize ACS care in the CKD population.